Table 2 Demographics and clinical characteristics of symptomatic APP duplication carriers (n = 41)
From: Phenotype and imaging features associated with APP duplications
Age at onset, years, mean ± SD | 50.8 ± 5.9 |
Age at death, years, mean ± SD | 58.6 ± 6.2 (n = 21) |
Sex, male (n %) | 25 (60.9%) |
First neurologic event | |
 ICH, n patients (%) | 5 (12.1%) |
 Cognitive decline, n patients (%) | 32 (78.0%) |
 Ischemic stroke, n patients (%) | 0 |
 Psychiatric symptoms n patients (%) | 2 (4.9%) |
 Seizures, n patients (%) | 2 (4.9%) |
Symptomatic lobar ICH | 12 (29.2%) |
 Age at 1st ICH (years, mean ± SD) | 47.2 ± 18.8 |
Seizure, n patients (%) | 21 (51.2%) |
Presence of cognitive decline, n patients (%) | 37 (90.2%) |
APOEgenotype | |
 APOE2 carriers n (%) | 3 (7.3%) |
 APOE4 carriers n (%) | 6 (14.6%) |
 APOE2 or 4 homozygous n (%) | 0 |
CSF biomarkers available,n(%) | 19 (46.3%) |
 Aβ-42 (pg/ml), mean ± SD | 378.1 ± 133.1 |
 Tau (pg/ml), mean ± SD | 600.5 ± 318.0 |
 Phospho-Tau (pg/ml), mean ± SD | 84.0 ± 39.3 |